• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, February 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Many European countries are not ready to stop viral hepatitis

Bioengineer by Bioengineer
April 18, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Many European countries lack a comprehensive policy to eliminate viral hepatitis as a major public health threat, according to a patient group-based survey implemented in 25 countries. The Hep-CORE study was coordinated by ISGlobal – an institution supported by the "la Caixa" Foundation – and led by the European Liver Patient's Association.

In 2016, viral hepatitis caused more deaths than HIV, malaria or tuberculosis. In the European Region, 18 and 15 million people live with chronic HBV and HCV infection, respectively. Due to widespread HBV vaccination, HBV infection is seen more in older Europeans or migrants from countries with high HBV prevalence. Regarding HCV – for which there is no vaccine -transmission is now mainly due to unsafe drug injection practices. New, highly effective direct?acting antiviral drugs have made HCV much easier and safer to cure, but they are costly and their availability remains a concern.

The World Health Organization (WHO) has called for the elimination of viral hepatitis as a major public health threat by 2030. But to reach this target, governments around the world must first consider whether they have the necessary policies and programmes in place.

A research team based at ISGlobal and the University of Copenhagen performed two rounds of surveys (in 2016 and 2017) with patient groups in 25 European countries, in order to assess policies and programmes that support elimination efforts.

Overall, the results indicate that many European countries have shortcomings across a wide range of elements, including national coordination, public awareness, disease surveillance, and treatment. In 2017, 72% of the countries were reported to have national HBV strategies and only half (52%) had national HCV strategies. Comparing 2016 and 2017, progress in government collaboration with civil society, disease registers, and access to direct-acting drugs for HCV was observed.

According to lead author Jeffrey Lazarus, who presented the study at the International Liver Congress 2018: "the patient?led Hep?CORE study offers a unique perspective on the readiness of these countries to undertake comprehensive viral hepatitis elimination efforts". The authors recommend that viral hepatitis monitoring should incorporate civil society perspectives, as has been done with global HIV monitoring.

###

Media Contact

Adelaida Sarukhan
[email protected]
34-932-271-816

http://www.isglobal.org/en/

https://www.isglobal.org/en/new/-/asset_publisher/JZ9fGljXnWpI/content/muchos-paises-europeos-no-estan-listos-para-frenar-la-hepatitis-viral

Related Journal Article

http://dx.doi.org/10.1002/jia2.25052

Share12Tweet7Share2ShareShareShare1

Related Posts

Succinate Receptor 1 Limits Blood Cell Formation, Leukemia

February 7, 2026

Palmitoylation of Tfr1 Drives Platelet Ferroptosis and Exacerbates Liver Damage in Heat Stroke

February 7, 2026

Oxygen-Enhanced Dual-Section Microneedle Patch Improves Drug Delivery and Boosts Photodynamic and Anti-Inflammatory Treatment for Psoriasis

February 7, 2026

Scientists Identify SARS-CoV-2 PLpro and RIPK1 Inhibitors Showing Potent Synergistic Antiviral Effects in Mouse COVID-19 Model

February 7, 2026
Please login to join discussion

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    57 shares
    Share 23 Tweet 14
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Succinate Receptor 1 Limits Blood Cell Formation, Leukemia

Palmitoylation of Tfr1 Drives Platelet Ferroptosis and Exacerbates Liver Damage in Heat Stroke

Oxygen-Enhanced Dual-Section Microneedle Patch Improves Drug Delivery and Boosts Photodynamic and Anti-Inflammatory Treatment for Psoriasis

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.